ecrin-mdr-crcClinical2014IPD Sharing (as of February 2019): NoColorectal CancerHead and Neck CancerHead and Neck NeoplasmsColorectal CancerHead And Neck NeoplasmsHead And Neck CancerInterventionalhttps://newmdr.ecrin.org/Study/2146162United States5NilotinibSquamous cell carcinomaMetastatic Kras wildtypeCetuximabECRIN MDRTerminatedfalseA Phase I Study of Nilontinib and Cetuximab in Patients With Solid TumorsThe purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.2014-05-152146162NCT01871311